IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call provided positive financial results, with a 12% revenue increase and improved net income and EPS. However, the slight decrease in gross margin and increased operating expenses may temper enthusiasm. The lack of strategic, operational, and risk discussions, combined with no additional insights from the Q&A, suggests limited new information to drive a strong stock price movement. With no market cap data, a neutral sentiment is appropriate, as positive financials are offset by operational cost increases and unchanged strategic outlook.
Key Financial Performance
Revenue $16.1 million, a 12% increase year-over-year, driven by strong demand for our MRI-compatible IV infusion pumps and patient monitors.
Gross Margin 78.5%, a slight decrease from 79.2% year-over-year, primarily due to increased production costs.
Net Income $4.2 million, a 10% increase year-over-year, attributed to higher revenue and effective cost management.
Earnings Per Share (EPS) $0.34, up from $0.31 year-over-year, reflecting improved profitability.
Operating Expenses $7.8 million, a 15% increase year-over-year, mainly due to investments in R&D and sales expansion.
Cash Flow from Operations $5.5 million, a 5% increase year-over-year, supported by strong operational performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO President
CFO Corporate
Capital Markets
Chairman CEO
Conference Instructions
Corporate Secretary
Division EDT
EDT Welcome
Founder Chairman
Frank Takkinen
Glenn CFO
IRadimed Financial
IRadimed Mr
IRadimed result
LLC Research
Lake Street
Markets LLC
Officer IRadimed
President Chief
President Glenn
Research Division
Roger Founder
Roger President
Secretary Frank
Street Capital
Takkinen Lake
Welcome IRadimed
replay day
report
result IRadimed
secgov Roger
secgov website
today IRadimed
IRMD Transcript
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call provided positive financial results, with a 12% revenue increase and improved net income and EPS. However, the slight decrease in gross margin and increased operating expenses may temper enthusiasm. The lack of strategic, operational, and risk discussions, combined with no additional insights from the Q&A, suggests limited new information to drive a strong stock price movement. With no market cap data, a neutral sentiment is appropriate, as positive financials are offset by operational cost increases and unchanged strategic outlook.
IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call summary and Q&A reveal strong financial performance with increased EPS and revenue, stable gross margins, and positive cash flow. The market feedback on the new 3870 MRI IV pump system is very positive, with additional orders already placed. The company also raised its financial guidance for the year, indicating confidence in future growth. These factors suggest a positive sentiment that will likely lead to a stock price increase of 2% to 8% over the next two weeks.
IRADIMED CORPORATION (IRMD) Q3 2025 Earnings Call Transcript
Positive11-3
The company reported strong financial performance with a 16% revenue increase and improved gross margins. Despite higher operational costs, the raised revenue and earnings guidance for 2025 and 2026, along with strategic growth plans, indicate optimism. The Q&A highlighted stable pricing and sufficient inventory, with plans for international expansion. The dividend declaration also supports a positive sentiment. However, concerns about operational costs and tax rate increases temper the outlook slightly. Overall, the sentiment is positive due to strong earnings, raised guidance, and strategic initiatives.
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
Positive8-1
The earnings call presents strong financial performance with revenue and EPS growth, a consistent gross margin, and increased domestic sales. The Q&A section reveals a solid backlog, positive sentiment towards the new product launch, and potential market expansion. However, international sales declined, and management was vague about the quantitative impact of the new pump. Despite these concerns, the overall sentiment is positive due to strong earnings, optimistic guidance, and a dividend announcement, suggesting a likely stock price increase in the next two weeks.
IRMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
